Literature DB >> 14627990

Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways.

Marta I Gallego1, Brian Bierie, Lothar Hennighausen.   

Abstract

Overexpression of hepatocyte growth factor (HGF), also called scatter factor (SF), and its receptor c-Met are associated with poor prognosis for cancer patients. In particular, breast cancer cells can produce HGF that acts in a paracrine as well as in an autocrine manner. Therefore, HGF and c-Met are putative targets for cancer therapy. To explore HGF/c-Met signaling in breast cancer, we have generated transgenic mice expressing HGF specifically in mammary epithelium under the transcriptional control of the whey acidic protein (WAP) gene promoter. WAP-HGF transgenic females developed hyperplastic ductal trees and multifocal invasive tumors after several pregnancies, some of which progressed to lung metastases. Tumors produced HGF and displayed phosphorylated c-Met, which correlated with increased Akt as well as c-myc activation. A high growth rate, as demonstrated by Ki67 nuclear antigen staining, and a lack of progesterone receptor were characteristic of the tumors. Immunohistochemical analysis revealed areas of osteopontin (Opn) expression in WAP-HGF tumors and lung metastases in agreement with a previously reported role for Opn in invasive growth. We suggest that these mice may serve as a new breast cancer model for the evaluation of the effects of unscheduled HGF expression in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627990     DOI: 10.1038/sj.onc.1207063

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.

Authors:  Sharon Moshitch-Moshkovitz; Galia Tsarfaty; Dafna W Kaufman; Gideon Y Stein; Keren Shichrur; Eddy Solomon; Robert H Sigler; James H Resau; George F Vande Woude; Ilan Tsarfaty
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

3.  LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.

Authors:  David L Shattuck; Jamie K Miller; Melanie Laederich; Melanie Funes; Heidi Petersen; Kermit L Carraway; Colleen Sweeney
Journal:  Mol Cell Biol       Date:  2006-12-18       Impact factor: 4.272

4.  Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Authors:  Carrie R Graveel; Jack D DeGroot; Yanli Su; Julie Koeman; Karl Dykema; Samuel Leung; Jacqueline Snider; Sherri R Davies; Pamela J Swiatek; Sandra Cottingham; Mark A Watson; Matthew J Ellis; Robert E Sigler; Kyle A Furge; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-30       Impact factor: 11.205

5.  Gene expression profiling of HGF/Met activation in neonatal mouse heart.

Authors:  Stefano Gatti; Christian Leo; Simona Gallo; Valentina Sala; Enrico Bucci; Massimo Natale; Daniela Cantarella; Enzo Medico; Tiziana Crepaldi
Journal:  Transgenic Res       Date:  2012-12-06       Impact factor: 2.788

6.  Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma.

Authors:  Wei Gao; Xue Bing; MingYan Li; Zhanhua Yang; Ying Li; Hua Chen
Journal:  Med Oncol       Date:  2013-03-28       Impact factor: 3.064

Review 7.  The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis.

Authors:  Kathryn J Rowland; Pamela M Choi; Brad W Warner
Journal:  Semin Pediatr Surg       Date:  2013-05       Impact factor: 2.754

8.  Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer.

Authors:  Jihong Ma; Marie C DeFrances; Chunbin Zou; Carla Johnson; Robert Ferrell; Reza Zarnegar
Journal:  J Clin Invest       Date:  2009-02-02       Impact factor: 14.808

Review 9.  The Met oncogene and basal-like breast cancer: another culprit to watch out for?

Authors:  Stefania Gastaldi; Paolo M Comoglio; Livio Trusolino
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

10.  Distinct gene-expression profiles characterize mammary tumors developed in transgenic mice expressing constitutively active and C-terminally truncated variants of STAT5.

Authors:  Tali Eilon; Itamar Barash
Journal:  BMC Genomics       Date:  2009-05-18       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.